Open AccessInhibition of Purified Recombinant Reverse Transcriptase from Wild‐Type and Zidovudine‐Resistant Clinical Isolates of Human Immunodeficiency Virus Type 1 by Zidovudine, Stavudine, and Lamivudine Triphosphates
Author(s) -
Chengying Duan,
David Poticha,
Thomas C. Stoeckli,
Christos J. Petropoulos,
Jeannette M. Whitcomb,
Charles S. McHenry,
Daniel R. Kuritzkes
Publication year - 2001
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1086/323995
Subject(s) - zidovudine , stavudine , lamivudine , virology , reverse transcriptase inhibitor , biology , drug resistance , reverse transcriptase , virus , viral disease , microbiology and biotechnology , sida , biochemistry , rna , hepatitis b virus , gene
Cross-resistance between zidovudine, stavudine, and lamivudine was studied, using purified recombinant reverse transcriptase from a zidovudine-susceptible and -resistant pair of clinical isolates of human immunodeficiency virus type 1. The zidovudine-resistant isolate exhibited low-level cross-resistance to both stavudine and lamivudine in drug susceptibility assays. Enzyme from the resistant isolate demonstrated reduced inhibition by zidovudine triphosphate and stavudine triphosphate and, to a lesser extent, lamivudine triphosphate. These findings provide additional evidence at the viral and enzyme level for cross-resistance between zidovudine and stavudine, and they suggest a possible effect of zidovudine resistance on susceptibility to lamivudine.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom